Pfizer Net Debt from 2010 to 2025

PFE Stock

USD 26.30 0.19 0.72%

Pfizer's Net Debt is increasing over the years with slightly volatile fluctuation. Overall, Net Debt is expected to go to about 87.2 B this year. Net Debt is the total debt of Pfizer Inc minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

1985-12-31

Previous Quarter

68.4 B

Current Value

65.5 B

Quarterly Volatility

19.6 B

Black Monday

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Pfizer financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pfizer's main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.6 B, Interest Expense of 2.7 B or Total Revenue of 39.5 B, as well as many indicators such as Price To Sales Ratio of 4.61, Dividend Yield of 0.0538 or PTB Ratio of 1.99. Pfizer financial statements analysis is a perfect complement when working with Pfizer Valuation or Volatility modules.

Check out the analysis of Pfizer Correlation against competitors.

Latest Pfizer's Net Debt Growth Pattern

Below is the plot of the Net Debt of Pfizer Inc over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Pfizer's Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pfizer's overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

Pfizer Net Debt Regression Statistics

	Arithmetic Mean	42,853,125,625
	Geometric Mean	29,249,477,850
	Coefficient Of Variation	50.58
	Mean Deviation	15,224,838,438
	Median	36,490,000,000
	Standard Deviation	21,674,698,687
	Sample Variance	469792563.2T
	Range	87.1B
	R-Value	0.80
	Mean Square Error	182084716.4T
	R-Squared	0.64
	Significance	0.0002
	Slope	3,637,105,515
	Total Sum of Squares	7046888447.7T

Pfizer Net Debt History

	2025	87.2 B
	2024	83 B
	2023	72.2 B
	2022	34.5 B
	2021	35.1 B
	2020	36.5 B
	2019	50.8 B

Other Fundumenentals of Pfizer Inc

Net Debt To E B I T D A

Pfizer Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Property Plant Equipment	Accounts Payable	Short Term Investments	Capital Stock	Common Stock	Long Term Debt	Good Will	Treasury Stock	Current Deferred Revenue	Net Tangible Assets	Total Permanent Equity	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital
Total Assets		0.97	0.87	0.83	0.45	0.99	0.55	0.55	0.91	0.79	0.9	0.28	0.88	0.88	0.91	0.76	-0.58	0.18	0.57	0.52	0.33	0.63	-0.37	0.14	0.31	0.03	0.57	-0.51
Total Stockholder Equity	0.97		0.76	0.8	0.53	0.91	0.65	0.38	0.84	0.79	0.88	0.4	0.85	0.85	0.83	0.69	-0.53	0.12	0.62	0.47	0.26	0.56	-0.39	0.17	0.14	-0.05	0.52	-0.41
Net Debt	0.87	0.76		0.84	0.08	0.91	0.14	0.73	0.87	0.62	0.86	-0.12	0.7	0.7	0.98	0.69	-0.61	0.07	0.6	0.61	0.6	0.75	-0.52	0.14	0.59	0.09	0.71	-0.76
Retained Earnings	0.83	0.8	0.84		0.1	0.82	0.25	0.49	0.66	0.65	0.94	0.03	0.78	0.78	0.85	0.72	-0.88	0.05	0.75	0.66	0.41	0.89	-0.71	0.28	0.41	-0.3	0.56	-0.53
Net Receivables	0.45	0.53	0.08	0.1		0.38	0.73	-0.02	0.33	0.65	0.29	0.36	0.5	0.5	0.19	0.42	-0.01	0.37	0.04	0.28	-0.13	-0.04	-0.02	-0.05	-0.12	-0.02	0.0	0.12
Total Liab	0.99	0.91	0.91	0.82	0.38		0.47	0.65	0.92	0.77	0.89	0.19	0.87	0.87	0.93	0.78	-0.6	0.22	0.52	0.53	0.37	0.65	-0.35	0.12	0.42	0.09	0.58	-0.55
Total Current Assets	0.55	0.65	0.14	0.25	0.73	0.47		-0.04	0.33	0.66	0.33	0.77	0.68	0.68	0.25	0.51	-0.2	0.28	0.1	0.02	-0.16	0.09	0.08	0.04	-0.23	0.06	0.05	0.26
Short Term Debt	0.55	0.38	0.73	0.49	-0.02	0.65	-0.04		0.64	0.38	0.47	-0.26	0.51	0.51	0.59	0.6	-0.43	0.34	-0.03	0.32	0.27	0.44	-0.16	-0.09	0.87	0.01	0.39	-0.67
Intangible Assets	0.91	0.84	0.87	0.66	0.33	0.92	0.33	0.64		0.68	0.81	0.07	0.7	0.7	0.88	0.66	-0.35	0.1	0.43	0.49	0.43	0.5	-0.23	-0.11	0.43	0.2	0.65	-0.6
Property Plant Equipment	0.79	0.79	0.62	0.65	0.65	0.77	0.66	0.38	0.68		0.71	0.13	0.88	0.88	0.67	0.93	-0.57	0.24	0.42	0.53	0.42	0.63	-0.35	0.12	0.31	0.07	0.57	-0.33
Accounts Payable	0.9	0.88	0.86	0.94	0.29	0.89	0.33	0.47	0.81	0.71		0.06	0.76	0.76	0.9	0.71	-0.71	-0.03	0.76	0.69	0.46	0.81	-0.65	0.13	0.36	-0.16	0.65	-0.52
Short Term Investments	0.28	0.4	-0.12	0.03	0.36	0.19	0.77	-0.26	0.07	0.13	0.06		0.31	0.31	-0.02	0.0	0.03	0.09	-0.02	-0.26	-0.51	-0.22	0.29	0.06	-0.52	-0.02	-0.27	0.46
Capital Stock	0.88	0.85	0.7	0.78	0.5	0.87	0.68	0.51	0.7	0.88	0.76	0.31		1.0	0.73	0.91	-0.73	0.44	0.38	0.5	0.18	0.66	-0.32	0.14	0.34	-0.09	0.38	-0.28
Common Stock	0.88	0.85	0.7	0.78	0.5	0.87	0.68	0.51	0.7	0.88	0.76	0.31	1.0		0.73	0.91	-0.73	0.44	0.38	0.5	0.18	0.66	-0.32	0.14	0.34	-0.09	0.38	-0.28
Long Term Debt	0.91	0.83	0.98	0.85	0.19	0.93	0.25	0.59	0.88	0.67	0.9	-0.02	0.73	0.73		0.68	-0.58	0.05	0.69	0.6	0.6	0.74	-0.54	0.2	0.44	0.13	0.71	-0.7
Good Will	0.76	0.69	0.69	0.72	0.42	0.78	0.51	0.6	0.66	0.93	0.71	0.0	0.91	0.91	0.68		-0.73	0.34	0.31	0.56	0.42	0.74	-0.39	0.06	0.57	-0.02	0.54	-0.4
Treasury Stock	-0.58	-0.53	-0.61	-0.88	-0.01	-0.6	-0.2	-0.43	-0.35	-0.57	-0.71	0.03	-0.73	-0.73	-0.58	-0.73		-0.22	-0.52	-0.61	-0.23	-0.84	0.65	-0.26	-0.44	0.45	-0.3	0.32
Current Deferred Revenue	0.18	0.12	0.07	0.05	0.37	0.22	0.28	0.34	0.1	0.24	-0.03	0.09	0.44	0.44	0.05	0.34	-0.22		-0.41	0.18	-0.44	-0.08	0.13	-0.18	0.22	-0.24	-0.48	0.13
Net Tangible Assets	0.57	0.62	0.6	0.75	0.04	0.52	0.1	-0.03	0.43	0.42	0.76	-0.02	0.38	0.38	0.69	0.31	-0.52	-0.41		0.46	0.58	0.71	-0.69	0.5	-0.07	-0.04	0.64	-0.46
Total Permanent Equity	0.52	0.47	0.61	0.66	0.28	0.53	0.02	0.32	0.49	0.53	0.69	-0.26	0.5	0.5	0.6	0.56	-0.61	0.18	0.46		0.37	0.64	-0.74	-0.12	0.49	-0.39	0.33	-0.35
Long Term Debt Total	0.33	0.26	0.6	0.41	-0.13	0.37	-0.16	0.27	0.43	0.42	0.46	-0.51	0.18	0.18	0.6	0.42	-0.23	-0.44	0.58	0.37		0.64	-0.49	0.22	0.41	0.43	0.9	-0.66
Capital Surpluse	0.63	0.56	0.75	0.89	-0.04	0.65	0.09	0.44	0.5	0.63	0.81	-0.22	0.66	0.66	0.74	0.74	-0.84	-0.08	0.71	0.64	0.64		-0.73	0.29	0.49	-0.15	0.69	-0.51
Deferred Long Term Liab	-0.37	-0.39	-0.52	-0.71	-0.02	-0.35	0.08	-0.16	-0.23	-0.35	-0.65	0.29	-0.32	-0.32	-0.54	-0.39	0.65	0.13	-0.69	-0.74	-0.49	-0.73		-0.18	-0.33	0.49	-0.41	0.38
Long Term Investments	0.14	0.17	0.14	0.28	-0.05	0.12	0.04	-0.09	-0.11	0.12	0.13	0.06	0.14	0.14	0.2	0.06	-0.26	-0.18	0.5	-0.12	0.22	0.29	-0.18		-0.17	0.13	0.21	-0.37
Short Long Term Debt	0.31	0.14	0.59	0.41	-0.12	0.42	-0.23	0.87	0.43	0.31	0.36	-0.52	0.34	0.34	0.44	0.57	-0.44	0.22	-0.07	0.49	0.41	0.49	-0.33	-0.17		-0.11	0.41	-0.63
Cash And Equivalents	0.03	-0.05	0.09	-0.3	-0.02	0.09	0.06	0.01	0.2	0.07	-0.16	-0.02	-0.09	-0.09	0.13	-0.02	0.45	-0.24	-0.04	-0.39	0.43	-0.15	0.49	0.13	-0.11		0.37	-0.16
Net Invested Capital	0.57	0.52	0.71	0.56	0.0	0.58	0.05	0.39	0.65	0.57	0.65	-0.27	0.38	0.38	0.71	0.54	-0.3	-0.48	0.64	0.33	0.9	0.69	-0.41	0.21	0.41	0.37		-0.71
Net Working Capital	-0.51	-0.41	-0.76	-0.53	0.12	-0.55	0.26	-0.67	-0.6	-0.33	-0.52	0.46	-0.28	-0.28	-0.7	-0.4	0.32	0.13	-0.46	-0.35	-0.66	-0.51	0.38	-0.37	-0.63	-0.16	-0.71

Click cells to compare fundamentals

About Pfizer Financial Statements

Pfizer stakeholders use historical fundamental indicators, such as Pfizer's Net Debt, to determine how well the company is positioned to perform in the future. Although Pfizer investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pfizer's assets and liabilities are reflected in the revenues and expenses on Pfizer's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pfizer Inc. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Net Debt	83 B	87.2 B
Net Debt To EBITDA	6.40	6.72

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:

How To Invest In Pfizer

Details

Is Pfizer Stock a good investment?

Details

What is Pfizer's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Pfizer Correlation against competitors.

You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.98)

Dividend Share

1.67

Earnings Share

0.75

Revenue Per Share

10.493

Quarterly Revenue Growth

0.312

The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pfizer Net Debt from 2010 to 2025

Latest Pfizer's Net Debt Growth Pattern

Pfizer Net Debt Regression Statistics

Pfizer Net Debt History

Other Fundumenentals of Pfizer Inc

Pfizer Net Debt component correlations

About Pfizer Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY